Latest Posts

NASHVILLE, Tenn. – (June 1, 2020) – PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced the availability of a new, minimally-invasive nasal swab collection option as a part of its comprehensive SARS-CoV-2 (COVID-19) testing program.

Many current molecular diagnostic COVID-19 tests rely on a nasopharyngeal (NP) swab, which can cause discomfort for patients during the collection process. The new nasal swab collection option is more comfortable for patients and easier for healthcare providers to administer.

Click here for more information.

It goes without saying that we are all facing unprecedented times in the face of the current COVID-19 epidemic. Like you, PathGroup is an essential component of the U.S. healthcare system and we remain fully operational to support the laboratory testing services of you and your patients.

To read more, click here.

Effective March 16, 2020, PathGroup will begin to offer testing for Coronavirus Disease 2019 (COVID-19).  This test is to be ordered only for individuals who meet the Centers for Disease Control and Prevention (CDC) Coronavirus Disease 2019 (COVID-19) clinical and/or epidemiological criteria for testing.  Because this criteria may change as more is learned about the virus, please refer directly to the CDC website for the most up-to-date patient testing criteria: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html

Click here for more information.

More than 50 million Americans suffer from allergies every year making allergies the sixth leading cause of chronic illness in the United States. Allergies are a common, yet overlooked, disease and the most common health issue that affects children in the U.S. An estimated 4.2 million children in the U.S. have a food allergy to things like peanuts, eggs, milk, wheat, tree nuts, fish and shellfish.

Click here to learn more!

PathGroup recognizes the efforts of the American Heart Association and healthcare providers in identifying, diagnosing and managing patients at risk for and impacted by heart disease.

 About 650,000 people in the United States die of heart disease every year, making it the leading cause of death in the U.S. The most common risk factors of heart disease are high blood pressure, high cholesterol, and smoking. Nearly 50% of Americans have at least one of these risk factors.

Click here for more information.

Along with our large community of Women’s Health providers, PathGroup recognizes January as Cervical Cancer Awareness Month and celebrates the efforts of these healthcare providers in screening, diagnosing, and treating women affected by cervical cancer.

 Over 13,000 new cases of invasive cervical cancer are diagnosed every year and it is most commonly diagnosed in women ages 35 to 44.  In 2019, an estimated 4,250 women died of cervical cancer. Before the introduction of the Pap test, cervical cancer was one of the most common causes of cancer death in women in the United States.

Click here to learn more.

Influenza, the most common respiratory virus, occurs in the fall and winter months spanning from mid-October to March in the United States. An estimated 40 million flu illnesses occurred during the 2018-2019 flu season in the U.S. which lasted nearly 21 weeks, the longest flu season in a decade.

Click here to learn more.

PathGroup recognizes November as Men’s Health Awareness Month, a month for male patients and their healthcare providers to communicate about common health conditions facing men in the United States.

Click here to learn more.

Along with our large community of Women’s Health providers, PathGroup recognizes October as Breast Cancer Awareness Month and celebrates the efforts of these healthcare providers in diagnosing and treating women affected by breast cancer.

 1 in 8 women in the United States will develop breast cancer in their lifetime making breast cancer the most common cancer among American women. About 270,000 new cases of breast cancer in women will be diagnosed in the United States in 2019 and nearly 42,000 women will die from the disease.

Click here to learn more.